This week Gilead Sciences slashed its 2020 revenue forecast, citing lower than expected demand for the COVID-19 drug Remdesivir. The company also said it was finding it difficult to predict sales of the drug, which is the only treatment in the U.S. that has been approved for patients who are hospitalized with COVID-19. The drug … Continue reading “Sales for Covid-19 Drug Remdesivir Fall Short Prompting Gilead to Cut 2020 Sales Outlook”
Tag: gilead
Biotech & Pharma
Gilead to Buy Cancer-drug Company Immunomedics for $21B
Over the weekend Gilead announced that it has agreed to purchase cancer-drug company Immunomedics for…
September 15, 2020
Biotech & Pharma
FDA is in Discussions with Gilead to Make Remdesivir Available As Quickly as Possible
At the rate of how many are being infected with coronavirus and how many are…
April 29, 2020
Biotech & Pharma
Gilead Shares Move Higher After FDA Approves its Cancer Drug
Gilead made an excellent move acquiring Kite Pharma because a drug that Kite developed has…
October 19, 2017